| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3406056 | Journal of Infection and Public Health | 2012 | 11 Pages |
Abstract
SummaryTargeting epidermal growth factor receptor (EGFR) is an important treatment option for non-small cell lung cancer (NSCLC).These targeted therapies have been studied extensively in NSCLC in first line and subsequent lines, including maintenance in empiric fashion or in patients with tumors harboring the EGFR mutations.In this manuscript, we will review in details the evolutions of these targeted therapy in the management of NSCLC.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Infectious Diseases
Authors
Ashwaq Al Olayan, Hamad Al Hussaini, Abdul Rahman Jazieh,